Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report).

Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...

Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.3 which represents a decrease of $-0.07 or -2.95% from the prior close of $2.37. The stock opened at $2.34 and touched a low of ...

Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.34 which represents a slight increase of $0.05 or 2.18% from the prior close of $2.29. The stock opened at $2.29 and ...

SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a biopharmaceutical company specializing in the development of oral treatments for inflammatory diseases, announced today that Martin Auster ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...